Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma - a Phase I/II Dose Escalation and Safety Study

NCT05449366 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT05449366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05449366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma - a Phase I/II Dose Escalation and Safety Study
Lead sponsor
Erasmus Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
February 1, 2022
Completion date
August 1, 2025
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peritoneal malignant mesothelioma